论文部分内容阅读
目的:探讨对非小细胞肺癌患者开展培美曲塞药物治疗工作期间,观察配合给予针对性护理干预后,获得的临床效果。方法:选择我院2015年03月~2017年02月收治的52例非小细胞肺癌患者作为实验对象;凭借数字奇偶法对本次研究收治的非小细胞肺癌患者分组;对照组:应用培美曲塞药物治疗非小细胞肺癌疾病过程中,配合选择常规方法施护;观察组:应用培美曲塞药物治疗非小细胞肺癌疾病过程中,配合选择针对性方法施护;对非小细胞肺癌患者治疗总有效率以及不良反应发生率回顾性分析。结果:同对照组非小细胞肺癌患者治疗总有效率(53.85%)比较,观察组非小细胞肺癌患者(84.62%)获得显著性增加(P<0.05)。同对照组非小细胞肺癌患者不良反应发生率比较,观察组非小细胞肺癌患者获得显著性降低(P<0.05)。结论:对于非小细胞患者在准备培美曲塞药物加以施治期间,配合应用针对性护理模式加以施护,对于肺癌治疗总有效的提高可以做出充分保证,从而优化非小细胞肺癌患者的预后能力。
OBJECTIVE: To investigate the clinical effects of pemetrexed therapy in patients with non-small cell lung cancer (NSCLC) treated with targeted nursing interventions. Methods: Fifty-two patients with non-small cell lung cancer who were treated in our hospital from March 2015 to February 2017 were enrolled as experimental subjects; patients with non-small cell lung cancer were divided into groups according to the numerical parity method; control group: Quercetin treatment of non-small cell lung cancer in the course of disease, with the choice of conventional methods of care; observation group: the application of pemetrexed drug treatment of non-small cell lung cancer disease process, with the choice of targeted methods of care; non-small cell lung cancer The total effective rate of patients and the incidence of adverse reactions were retrospectively analyzed. Results: Compared with the control group, the total effective rate (53.85%) in non-small cell lung cancer patients was significantly increased (84.62%) (P <0.05). Compared with the incidence of adverse reactions in non-small cell lung cancer patients in the control group, the patients in the non-small cell lung cancer group were significantly reduced (P <0.05). CONCLUSIONS: During the course of preparation of pemetrexed medications for non-minicell patients and in combination with targeted care modalities, adequate assurance of overall effective treatment of lung cancer can be made to optimize the management of patients with non-small cell lung cancer Prognostic ability.